(Q43063702)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467920%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Management of disease- and treatment-related complications in patients with multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467920%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467920%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

2

Antonio Palumbo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467920%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

1 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467920%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467920%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

27 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467920%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

S43-52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20467920%20AND%20SRC:MED&resulttype=core&format=json

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

2 February 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12032-010-9542-Z

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

12 December 2020

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Renal Failure in Multiple Myeloma

1 reference

12 December 2020

1 reference

12 December 2020

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

1 reference

12 December 2020

Thalidomide for treatment of multiple myeloma: 10 years later

1 reference

12 December 2020

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

12 December 2020

Guidelines on the diagnosis and management of multiple myeloma 2005.

1 reference

12 December 2020

Osteonecrosis of the jaw and the role of bisphosphonates: a critical review

1 reference

12 December 2020

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

12 December 2020

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

1 reference

12 December 2020

Stem-cell transplantation for multiple myeloma in the era of novel drugs

1 reference

12 December 2020

The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement

1 reference

12 December 2020

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

1 reference

12 December 2020

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

1 reference

12 December 2020

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

12 December 2020

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

12 December 2020

Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma

1 reference

12 December 2020

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

12 December 2020

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

12 December 2020

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

1 reference

12 December 2020

Radiation therapy for the palliation of multiple myeloma

1 reference

12 December 2020

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

12 December 2020

Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease

1 reference

12 December 2020

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

1 reference

12 December 2020

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

12 December 2020

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

12 December 2020

Complications of multiple myeloma

1 reference

12 December 2020

Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis

1 reference

12 December 2020

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

1 reference

12 December 2020

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

1 reference

12 December 2020

VAD-based regimens as primary treatment for multiple myeloma

1 reference

12 December 2020